[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nazarii Kobyliak\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100645460","diabetes-glycemic-assessment-in-newly-confirmed-episodes-100645460",false,"NCT07690163","DIabetes GLycemic Assessment in Newly Confirmed Episodes","Evaluation of Continuous Glucose Monitoring Systems for Optimizing Glycemic Control in Patients With Newly Diagnosed Type 2 Diabetes: A Postmarketing Clinical Analysis","DI-GLANCE","Inclusion Criteria:\n\n* Age of 18 years and older.\n* Newly diagnosed Type 2 Diabetes Mellitus according to ADA (American Diabetes Association) criteria (Fasting Plasma Glucose ≥ 7.0 mmol\u002FL, or 2-hour Post-Prandial Glucose ≥ 11.1 mmol\u002FL during OGTT, or HbA1c ≥6.5%).\n* Time since the initial diagnosis of T2D must not exceed 3 months ( less 90 days) at the time of screening.\n* HbA1c level between 6.5% and 9.5% (inclusive) at screening.\n* Patients may be lifestyle-controlled or receiving any stable non-insulin anti-diabetic therapy (including Metformin, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, or Sulfonylureas) as monotherapy or combination therapy.\n* Ability to provide written informed consent and willingness to adhere to the study protocol and follow-up schedule.\n\nExclusion Criteria:\n\n* Diagnosis or suspicion of Type 1 Diabetes, Latent Autoimmune Diabetes in Adults (LADA) (e.g., positive anti-GAD antibodies if tested), or secondary types of diabetes (e.g., pancreatic or drug-induced).\n* Any prior or current use of insulin therapy.\n* Severe microvascular or macrovascular complications (proliferative retinopathy, severe diabetic nephropathy with eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m², diabetic foot ulcers, severe peripheral neuropathy).\n* Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia.\n* History of myocardial infarction, stroke, unstable angina, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI) within the past 6 months.\n* Active malignancy, decompensated heart failure (NYHA Class III or IV), or chronic infectious diseases.\n* Pregnant or breastfeeding women, or women of childbearing potential not using highly effective contraception.\n* Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant.\n* Participation in another clinical study within the last 3 months.","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, open-label, randomized controlled trial involving 80 adult patients with newly diagnosed T2DM (diagnosed within the last 3 months) recruited at the Bogomolets National Medical University. Participants may be lifestyle-controlled or receiving stable non-insulin anti-diabetic medications. Participants will be randomized in a 1:1 ratio to either the Real-Time Continuous Glucose Monitoring group (CGM group) or the control group (standard Self-Monitoring of Blood Glucose \\[SMBG\\] using conventional glucometers).\n\nThe gathered data will help determine whether the real-time visual feedback provided by CGM systems superiorly improves glycemic variability, optimizes metabolic parameters, and enhances patient adherence to lifestyle interventions and pharmacological treatment compared to conventional SMBG methods in the early stages of T2D.",[27,28,29,30],"Type 2 Diabetes (T2DM)","Obesity Type 2 Diabetes Mellitus","Obesity & Overweight","Insulin Resistance",[32,33,34,35,36],"obesity","continuous glucose monitoring","insulin resistance","traditional glycemia self-monitoring","type 2 diabetes","RECRUITING","2026-07-11",{"date":40,"type":41},"2026-07-14","ACTUAL",{"date":43,"type":21},"2026-07-15",{"date":45,"type":21},"2027-03-31",{"name":47,"class":48},"Nazarii Kobyliak","OTHER",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":49},"100639897","prediabetes-glycemic-impact-and-data-evaluation-100639897","NCT07599072","PREdiabetes GLycemic Impact and Data Evaluation","Evaluation of the Impact of Continuous Glucose Monitoring (CGM) Systems on Glycemic Control in People With Prediabetes: Postmarketing Clinical Study","PRE-GLIDE","Inclusion Criteria:\n\n* Age of 18 years and older.\n* Presence of prediabetes diagnosed according to criteria of the American Diabetes Association\n* Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study;\n* Ability to comply with protocol requirements and maintain a patient diary.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of type 1 or type 2 diabetes;\n* Decompensated liver or kidney diseases (GFR \\\u003C 45 ml\u002Fmin\u002F1. 73 m²);\n* Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study;\n* Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia;\n* Pregnancy or lactation;\n* Mental or cognitive impairments that would interfere with study participation;\n* Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months;\n* Recent use of any CGM within the last 12 months;\n* Known allergy to sensor materials;\n* Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant;\n* Participation in another clinical study within the last 3 months.",{"count":20,"type":21},[24],"This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.",[62,29,30],"Pre Diabetic",[64,32,33,34,35],"prediabetes","2026-06-29",{"date":67,"type":41},"2026-06-30",{"date":69,"type":21},"2026-07-01",{"date":71,"type":21},"2027-06-30",{"name":47,"class":48},""]